- Home
- CRMD vs STTK Comparison
CRMD vs STTK Comparison
Compare CRMD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRMD | STTK |
|---|---|---|
| Founded | 2006 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 590.7M | 652.4M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CRMD | STTK |
|---|---|---|
| Price | $5.67 | $5.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | $14.83 | ★ $15.40 |
| AVG Volume (30 Days) | ★ 1.6M | 1.0M |
| Earning Date | 11-12-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 780.00 | 53.02 |
| EPS | ★ 0.72 | N/A |
| Revenue | ★ $311,709,000.00 | $1,000,000.00 |
| Revenue This Year | $7.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.62 | ★ N/A |
| Revenue Growth | ★ 617.03 | N/A |
| 52 Week Low | $5.30 | $1.72 |
| 52 Week High | $13.02 | $8.33 |
Technical Indicators
Market Signals| Indicator | CRMD | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 26.70 | 42.74 |
| Support Level | N/A | $5.19 |
| Resistance Level | $8.81 | $7.59 |
| Average True Range (ATR) | 0.48 | 0.34 |
| MACD | -0.24 | 0.02 |
| Stochastic Oscillator | 8.51 | 32.05 |
Price Performance
Historical ComparisonAbout CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.